Bristol-Myers Squibb Company (BMY) Gains After Deep Q3 Earnings
Bristol-Myers Squibb Company (BMY) gains after a deep Q3 earnings review showing beats on EPS and revenue, stronger growth-brand sales, and raised revenue guidance. The analysis also weighs margin pressure, lower EPS guidance, and the ongoing shift away from legacy products.
Bristol-Myers Squibb Company (NYSE: BMY) beat third-quarter earnings and revenue estimates, with adjusted EPS of $1.35 and revenue of $13.07 billion. The stock rose modestly because investors saw strong growth from newer drugs and higher revenue guidance, but the lower full-year EPS outlook and weaker gross margin kept enthusiasm in check.
Bristol-Myers Squibb Company (BMY) Gains on Q3 Earnings
Bristol-Myers Squibb Company (BMY) beat both earnings and revenue estimates in the third quarter of 2026. Adjusted EPS reached $1.35 versus a $1.10 estimate, while revenue came in at $13.07B against a $12.72B consensus.
The stock gained 0.56% to $60.91 during regular trading on Oct. 29, 2026. The modest move reflects a mixed setup: strong growth brands and higher revenue guidance competed with lower EPS guidance and weaker gross margins.
Key Takeaways
BMY reported adjusted EPS of $1.35, ahead of the $1.10 estimate, and revenue of $13.07B, above the $12.72B consensus.
Growth portfolio revenue rose 12% to $7.7B. Reblozyl, Breyanzi, Qvantig, Camzyos, and Opdualag drove the strongest product momentum.
Eliquis revenue increased 26% to $4.7B, while Opdivo revenue fell 6% to $2.4B as patients continued shifting to Qvantig.
BMY raised 2026 revenue guidance to $49.75B-$50.25B from $49.0B-$50.0B, but lowered adjusted EPS guidance to $6.35-$6.55 from $6.75-$7.00.
Gross margin fell to 68.4% because of product mix and a one-time contract termination expense. Operating expenses totaled $4.1B.
Analyst consensus remained Hold, with 19 Buy ratings, 21 Hold ratings, and 2 Sell ratings. The balance shows respect for BMY's pipeline, but caution around margins and legacy-product erosion.
The quarter's headline numbers were solid. Revenue increased 7% year over year to $13.1B, according to CFO David Elkins. The $13.07B reported figure also topped consensus. Revenue reached $12.97B in the second quarter and $11.49B in the first quarter, giving BMY a stronger top line than earlier in 2026.
The mix matters more than the total. Growth portfolio revenue rose 12% to $7.7B. Legacy portfolio revenue increased 1% to $5.4B, with Eliquis growth more than offsetting generic competition across older products. This is the central operating story behind the BMY earnings report: newer brands are expanding, while the established portfolio requires careful management.
Product performance was broad. Reblozyl revenue increased 22% to $750M, supported by demand in first-line MDS-associated anemia. Breyanzi revenue rose 48% to $526M. Qvantig generated $334M, up 28% sequentially, and now carries an annualized revenue run rate above $1.3B. Opdivo revenue declined 6% to $2.4B as conversion to Qvantig continued in the U.S. and Europe.
Eliquis remained the quarter's largest product engine. Revenue reached $4.7B, up 26%, supported by net price, demand, and market share gains. However, BMY expects the upcoming loss of exclusivity in Europe to affect fourth-quarter Eliquis sales. Camzyos revenue grew 42% to $420M, although third-quarter inventory drawdown reduced sequential sales. Sotyktu revenue increased 25%, while Cobenfy revenue rose 33% to $57M.
Profitability was less impressive than revenue. Gross margin was 68.4%, compared with 72.9% in the prior-year comparison cited in same-day coverage. BMY attributed the decline to product mix and a one-time contract termination expense. The company also reported a 14.1% effective tax rate and a $0.58 per-share impact from acquired in-process research and development and licensing income.
The call's non-GAAP diluted EPS was $1.35. The quarterly financial series lists EPS of $1.62 for the second quarter and $1.31 for the first quarter, while the earnings surprise history records adjusted figures of $2.04 and $1.58 for those periods. The different series highlight why investors must separate GAAP results from the non-GAAP measure used for BMY's guidance.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Market Reaction and Analyst Response to BMY Earnings
BMY shares traded at $60.91 at 3:30 p.m. ET on Oct. 29, up 0.56%. Volume reached 8,948,378 shares versus an average of 11,583,248. That measured reaction fits the earnings profile: the company beat estimates and raised revenue guidance, but the lower EPS outlook limits the case for an immediate rerating.
The analyst consensus was Hold. Nineteen analysts rated BMY Buy, 21 rated it Hold, and 2 rated it Sell. The distribution points to a split view. Analysts recognize the 12% growth portfolio increase and the pipeline progress, yet the forecast calls for a 3% to 5% decline in full-year legacy portfolio revenue.
The most important debate is not whether BMY can produce growth. The third-quarter numbers answer that question. The debate is whether new products can grow fast enough to replace the earnings pressure from mature brands, European Eliquis exclusivity changes, and lower margins.
CEO Christopher Boerner framed the quarter as a transition from product concentration toward a broader growth base. BMY now has eight growth portfolio medicines each generating an annualized revenue run rate above $1B based on third-quarter sales. The company also highlighted positive registrational data for Symvexis, admilparant, RAISE 101, and Arlocell.
"Our growth portfolio continues to deliver solid results with sales increasing 12%." - Christopher S. Boerner, CEO, Earnings Call
Boerner also pointed to longer-term infrastructure. BMY announced an approximately $2.3B manufacturing campus in Houston and more than $170M for a radiopharmaceutical facility in Indiana. Those investments support small molecules, biologics, antibody-drug conjugates, and radiopharmaceutical production.
"We remain focused on financial discipline, balancing investments in our growth drivers with continued productivity improvements." - David V. Elkins, CFO, Earnings Call
Elkins' financial message was more complicated. BMY raised revenue guidance because of year-to-date execution, but the $0.58 per-share acquired research and development and licensing item pushed down the reported EPS outlook. Excluding that item, the midpoint of EPS guidance would have increased by approximately $0.15 per share. BMY ended the quarter with approximately $13B in cash and marketable securities and generated roughly $4.2B in operating cash flow.
Michael Yee of UBS focused on admilparant for idiopathic pulmonary fibrosis. He pressed management on confidence in the 120 mg dose and on the 60 mg and 120 mg doses in the progressive pulmonary fibrosis study. The question went to the heart of pipeline risk: a positive initial readout must translate into a reliable late-stage development path.
"Confidence in the 120 mg high dose" - Michael Yee, UBS
Boerner's broader response emphasized that admilparant met its primary endpoint at the 60 mg dose and showed a favorable safety and tolerability profile. BMY expects phase 3 progressive pulmonary fibrosis results in the first quarter of 2027, giving this program a defined near-term development milestone.
Alex Hammond of Wolfe Research shifted the discussion to commercialization. He asked about the early launch of Birdamide and the expected 2027 approval of Mesi, focusing on uptake, tolerability, and physician feedback. The question tested whether BMY's pipeline can become a revenue engine rather than simply a collection of promising clinical assets.
"Uptake, tolerability, and physician feedback" - Alex Hammond, Wolfe Research
Evan Seigerman of BMO Capital Markets challenged BMY on business development spending. He asked whether the company's approach reflected valuation discipline, confidence in the internal pipeline, or the need to fill the loss-of-exclusivity gap. Management's position was that business development remains a priority, but investments must fit therapeutic areas where BMY has expertise.
"Pursue business development where it makes sense." - Christopher S. Boerner, CEO, Earnings Call
BMY's third-quarter earnings show a business gaining momentum in newer medicines, with a clear beat on EPS and revenue. Still, the lower 2026 EPS outlook and gross-margin pressure keep the stock in a prove-it phase.
The investment case now rests on execution: Qvantig, Reblozyl, Breyanzi, Camzyos, and the broader pipeline must offset legacy declines while BMY preserves cash for development, business development, and its dividend.
+Did Bristol-Myers Squibb (BMY) beat earnings in Q3 2026?
Yes. Bristol-Myers Squibb reported adjusted EPS of $1.35, above the $1.10 consensus estimate, and revenue of $13.07 billion versus the $12.72 billion forecast. The company also said revenue rose 7% year over year.
+Why did BMY stock only rise slightly after the earnings report?
BMY shares gained just 0.56% to $60.91 because the quarter was mixed despite the beat. Investors liked the stronger revenue and growth-brand momentum, but the company lowered full-year adjusted EPS guidance and gross margin fell to 68.4%.
+What did Bristol-Myers Squibb change in its 2026 guidance?
Bristol-Myers Squibb raised 2026 revenue guidance to $49.75 billion-$50.25 billion from $49.0 billion-$50.0 billion. At the same time, it lowered adjusted EPS guidance to $6.35-$6.55 from $6.75-$7.00.
+Which BMY drugs drove growth in the third quarter?
The growth portfolio rose 12% to $7.7 billion, led by Reblozyl, Breyanzi, Qvantig, Camzyos, and Opdualag. Eliquis also increased 26% to $4.7 billion, while Opdivo fell 6% to $2.4 billion as patients shifted to Qvantig.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on BMY?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
